医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medidata to Participate in U.S. Trade Mission to Japan and South Korea, Supporting Stronger Economic Ties in Healthcare and Energy Sectors

2014年10月21日 PM09:30
このエントリーをはてなブックマークに追加


 

NEW YORK

Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that Bryan Spielman, Medidata’s executive vice president of strategy and corporate development, and Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific region, will join U.S. Secretary of Commerce Penny Pritzker on her first trade mission to Asia since taking office in June 2013. The mission will focus on business development opportunities in the healthcare and energy sectors in Japan and South Korea, underscoring the U.S. administration’s ongoing efforts to strengthen commercial ties across Asia.

“The 20 American companies joining us on this trade mission are leaders and innovators in healthcare and energy, and they have the expertise and resources to serve as partners to Japan and Korea in these two critical sectors,” said U.S. Secretary of Commerce Penny Pritzker. “These companies share a desire to do more business in Japan and Korea, to develop new and deeper partnerships here, and to make investments in this market for the long-term. Throughout this trade mission to Japan and Korea, our American business leaders will help deepen and strengthen our commercial ties in the Asia-Pacific region, while also finding new markets for their goods and services.”

Along with representatives from other U.S.-based firms, including Abbott, Eli Lilly and Merck & Co, Spielman will participate in a program designed to connect U.S. healthcare and life science companies with those in Japan and Korea and stimulate collaborative business opportunities. His participation exemplifies Medidata’s commitment to enabling life science organizations in Japan and Korea—and all areas of the world—to transform their clinical trials through the Medidata Clinical Cloud™, the company’s platform of advanced technologies and data analytics.

“Our mission is to help life science organizations everywhere deliver safe, new medicines to patients as quickly as possible, so we’re proud to be working closely with a growing number of life science organizations in Japan and Korea,” Spielman said. “I’m looking forward to spending time in both countries, exploring how Medidata can continue to further support more companies with their drug development programs.”

Medidata’s managing director for the Asia-Pacific region, Takeru Yamamoto, added: “Regulatory authorities across the globe are progressively requiring electronic submission of data from clinical trials and, by 2016, it will be mandatory in Japan. As a global leader in clinical trial software solutions, Medidata has unmatched expertise and experience in electronic collection, management and submission of clinical study data. We are delighted that our solutions are helping an ever-increasing number of Japanese and Korean companies accelerate their clinical trials and bring their life-saving therapies to market globally.”

Connect with Medidata:

About Medidata Solutions

Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

CONTACT

Medidata Solutions
Investors:
Hulus Alpay, 212-419-1025
halpay@mdsol.com
or
Media:
Nicole
Pariser, 212-659-1069
npariser@mdsol.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc